Profund Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $571K | Buy |
63,711
+9,730
| +18% | +$87.2K | 0.02% | 431 |
|
|
2025
Q1 | $405K | Buy |
53,981
+6,231
| +13% | +$46.7K | 0.02% | 547 |
|
|
2024
Q4 | $359K | Sell |
47,750
-26,753
| -36% | -$201K | 0.01% | 678 |
|
|
2024
Q3 | $566K | Sell |
74,503
-12,312
| -14% | -$93.6K | 0.02% | 487 |
|
|
2024
Q2 | $537K | Sell |
86,815
-155,057
| -64% | -$958K | 0.02% | 478 |
|
|
2024
Q1 | $1.23M | Buy |
241,872
+86,483
| +56% | +$439K | 0.05% | 305 |
|
|
2023
Q4 | $931K | Buy |
155,389
+18,737
| +14% | +$112K | 0.04% | 340 |
|
|
2023
Q3 | $967K | Sell |
136,652
-40,240
| -23% | -$285K | 0.05% | 293 |
|
|
2023
Q2 | $1.25M | Buy |
176,892
+24,138
| +16% | +$170K | 0.07% | 268 |
|
|
2023
Q1 | $1.27M | Buy |
+152,754
| New | +$1.27M | 0.08% | 236 |
|